Bristol Myers Squibb (CELG-RI) EBITDA Margin (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of EBITDA Margin data on file, last reported at 24.65% in Q1 2026.

• EBITDA Margin for Q1 2026 came in at 24.65%, up 437.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 15.12% (up 379.0% YoY), and the FY2025 annual result was 14.04%, up 3193.0% from the prior year.
• EBITDA Margin grew to 24.65% in Q1 2026 per CELG-RI's latest filing, from 8.6% in the prior quarter.
• Over five years, EBITDA Margin peaked at 24.65% in Q1 2026 and troughed at 99.16% in Q1 2024.
• A 5-year average of 7.77% and a median of 13.87% in 2022 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2024 and 2025: EBITDA Margin slumped 11834 bps in 2024, then jumped 11943 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 13.87% in 2022, then fell by 6 bps to 13.09% in 2023, then sank by 81 bps to 2.45% in 2024, then surged by 251 bps to 8.6% in 2025, then jumped by 187 bps to 24.65% in 2026.
• Business Quant data shows CELG-RI's EBITDA Margin at 24.65% in Q1 2026, 8.6% in Q4 2025, and 18.34% in Q3 2025.